CASSS Sharing Science Solutions CE Pharm 2025

Capillary Electrophoresis • CE-MS • icIEF • CGE • Biopharmaceutical Analysis • mRNA • ADCs • Regulatory Science

Explore advanced analytical applications of capillary electrophoresis in modern biopharmaceutical development with CASSS Sharing Science Solutions CE Pharm 2025, formally titled CE in the Biotechnology & Pharmaceutical Industries: Symposium on the Practical Applications for the Analysis of Proteins, Nucleotides & Small Molecules.

Organized by CASSS – Sharing Science Solutions, CE Pharm 2025 was held September 7–10, 2025, in Bethesda, Maryland, United States. The meeting brought together specialists from the biopharmaceutical industry, academia, analytical technology organizations, and regulatory agencies to discuss practical and emerging applications of capillary electrophoresis.

The program focused on technologies and workflows including capillary zone electrophoresis (CZE), capillary gel electrophoresis (CGE/CE-SDS), capillary isoelectric focusing (CIEF/icIEF), CE-MS, native fluorescence detection, mRNA characterization, plasmid analysis, antibody-drug conjugates, monoclonal antibodies, virus-like particles, analytical method validation, peak integration, critical reagents, and regulatory considerations.

---

Course Details

• Program: CE Pharm 2025
• Organizer: CASSS – Sharing Science Solutions
• Full Title: CE in the Biotechnology & Pharmaceutical Industries: Symposium on the Practical Applications for the Analysis of Proteins, Nucleotides & Small Molecules
• Year: 2025
• Dates: September 7–10, 2025
• Location: Bethesda, Maryland, United States
• Field: Biopharmaceutical Analytical Science
• Primary Focus: Capillary Electrophoresis
• Format: In-Person with Livestreamed Scientific Sessions
• Short Course: Capillary Electrophoresis Fundamentals and Protein Therapeutic Applications
• Language: English

The official schedule shows a dedicated CE fundamentals short course on September 7, followed by keynote lectures, scientific sessions, panel discussions, roundtables, posters, technical seminars, and a troubleshooting workshop during the main symposium.

---

Course Overview

Capillary electrophoresis is widely used in pharmaceutical and biotechnology development because it can provide high-resolution separation and characterization of proteins, nucleic acids, biotherapeutics, vaccines, and other complex products.

CE Pharm 2025 examines applications of CE across:

Method Development → Product Characterization → Process Development → Quality Control → Lot Release → Stability Testing → Regulatory Submission

CASSS specifically identifies applications in:

• High-throughput screening
• Formulation studies
• Process development
• Product characterization
• Validated lot-release testing
• Stability testing

The program also explores how newer technologies such as CE-MS, native fluorescence, high-throughput CGE, and advanced icIEF can extend the analytical capabilities of traditional CE platforms.

---

Learning Objectives

Upon completion of this program, participants should be better able to:

• Apply advanced charge heterogeneity profiling and mass spectrometry (CE-MS) methodologies for analyzing Antibody-Drug Conjugates (ADCs) and monoclonal antibodies.
• Optimize Capillary Gel Electrophoresis (CGE) and native fluorescence detection techniques to evaluate RNA, mRNA integrity, and protein quantification in conjugate vaccines.
• Navigate regulatory considerations, including leveraging prior knowledge in analytical method development, adhering to ICH Q2 R2 guidelines, and effectively communicating CE method issues to QA and management.
• Develop and validate high-performance separation techniques for complex biotherapeutics, including mRNA vaccines, plasmid topologies, and virus-like particles.
• Implement robust strategies for critical reagent management, peak integration challenges, and CE method troubleshooting within a biopharmaceutical setting.

---

CE Pharm 2025 Scientific Program

The official scientific program was organized around several major themes:

• Applications and advancements in CE innovations
• Cell and gene therapy analytical applications
• Regulatory science
• New therapeutic modalities
• icIEF and charge analysis
• Next-generation investigators
• CE-MS and product characterization
• Roundtable discussions
• Troubleshooting

The symposium also featured keynote lectures from J. Michael Ramsey, University of North Carolina at Chapel Hill, and Joel Welch, FDA CDER.

---

Capillary Electrophoresis Fundamentals

The September 7 short course provided a structured introduction and review of CE principles and pharmaceutical applications.

Major areas included:

• CE fundamentals
• Separation mechanisms
• Good working practices
• Critical operating parameters
• Pharmaceutical development applications
• Process-development applications
• Product characterization
• QC lot-release testing
• Stability testing

The course specifically reviewed major CE modes including:

• Capillary Zone Electrophoresis – CZE
• Capillary Gel Electrophoresis – CE-SDS / CGE
• Capillary Isoelectric Focusing – CIEF
• Capillary Electrophoresis-Mass Spectrometry – CE-MS

---

Applications & Advancements in CE Innovations

The first major scientific session focused on new applications and technical improvements in capillary electrophoresis.

Official presentations included:

• Capillary Gel Electrophoresis for Gardasil and Gardasil®9 Purity Determination
• Advancement of Capillary Gel Electrophoresis Through the Use of Native Fluorescence Detection
• Charge Heterogeneity Analysis of Antibody Drug Conjugates: Capillary Zone Electrophoresis

These presentations demonstrate how CE can be applied to vaccines, protein products, and antibody-drug conjugates.

---

Antibody-Drug Conjugates – ADCs

ADCs represent analytically complex biotherapeutics because conjugation can create substantial molecular heterogeneity.

The CE Pharm program included multiple approaches for ADC analysis, including:

• Capillary zone electrophoresis
• icIEF
• Fractionation
• Mass spectrometry
• Charge heterogeneity analysis
• Sample stability assessment

One official presentation evaluated charge heterogeneity of ADCs using CZE, while another examined improving ADC stability during icIEF analysis by adjusting the separation-matrix pH.

A practical analytical strategy can include:

Sample Preparation → CE Separation → Charge Profile → Peak Identification → MS Characterization → Data Interpretation

---

Advanced Charge Heterogeneity Analysis

Charge heterogeneity is an important quality attribute for many therapeutic proteins and antibody-based products.

The program included:

• CZE-based charge analysis
• icIEF
• Direct icIEF fractionation
• NanoLC-MS/MS peptide mapping
• Proteoform analysis
• Charge-variant identification

The official session From Peak to Shining Peak: Traversing the cIEF Landscape included work from Genentech, Bristol Myers Squibb, and AstraZeneca on therapeutic antibodies, ADCs, and charge identification.

---

CE-MS

The combination of capillary electrophoresis and mass spectrometry provides both high-resolution separation and molecular identification.

CE Pharm 2025 included dedicated roundtables on:

CE-MS – Current Trends and Applications in Biopharmaceutical Development

as well as a scientific session dedicated to CE-MS, peak identification, and product characterization.

CE-MS can be useful for:

• Proteoform characterization
• Charge-variant identification
• Monoclonal antibody analysis
• ADC characterization
• Protein identification
• Molecular heterogeneity assessment

---

Monoclonal Antibody Proteoforms

The official CE-MS program included:

High-Performance Native Separation of mAb Proteoforms by CZE-MS Under Native and Denaturing nanoESI Conditions for Ultrasensitive Charge Variant Characterization

This presentation demonstrates the use of CZE-MS to characterize monoclonal-antibody proteoforms under different separation and electrospray conditions.

---

Advanced ADC Profiling by icIEF-MS

Another official CE-MS presentation addressed:

Advanced Charge Heterogeneity Profiling of Antibody Drug Conjugates via icIEF Fractionation and Mass Spectrometry

combining charge-based separation with mass-spectrometric characterization.

This workflow illustrates the analytical sequence:

icIEF Separation → Charge Fractionation → Mass Spectrometry → Proteoform Identification

---

Native Fluorescence Detection

Native fluorescence detection was an important technology theme at CE Pharm 2025.

The program included:

• Multi-capillary CE with native fluorescence
• Label-free protein detection
• CE-SDS applications
• Charge-based CE applications
• Improvements in analytical sensitivity
• Workflow simplification

A SCIEX technical seminar featured BioPhase 8800 System: Advancing Capillary Electrophoresis With Native Fluorescence Detection and Label-Free Native Fluorescence for High-Sensitivity Protein Analysis Using a Multi-Capillary Electrophoresis System.

---

CGE – Capillary Gel Electrophoresis

CGE was used across several applications represented in the 2025 program.

Examples included:

• Vaccine purity
• RNA integrity
• mRNA characterization
• Free-protein quantification
• Plasmid analysis
• Protein therapeutics

The official roundtable program also included:

SDS-CGE and CGE Method Development and Application.

---

RNA & mRNA Characterization

The Cell and Gene Therapy scientific session included multiple nucleic-acid applications.

Official presentations included:

• A Tale of Tails: Using the Power of Capillary Electrophoresis for the Analytical Characterization of mRNA
• Development and Optimization of a CGE-LIF Method for RNA Integrity Characterization using SCIEX 9000 RNA Kit
• High-Throughput Plasmid DNA Isoform Analysis Using Capillary Gel Electrophoresis

These applications illustrate how CE can support:

• RNA integrity assessment
• mRNA characterization
• Nucleic-acid size distribution
• Plasmid topology analysis
• Product-development analytics

---

mRNA Vaccine Applications

The roundtable program included dedicated discussions on:

mRNA Vaccine CE Applications

in both roundtable sessions.

CE-based methods can provide analytical information related to:

• RNA integrity
• Molecular size
• Product degradation
• Method parameters
• Stability
• Quality-control strategies

---

Plasmid DNA Analysis

Plasmid DNA topology and isoform characterization were also represented.

The official program included:

High-Throughput Plasmid DNA Isoform Analysis Using Capillary Gel Electrophoresis

and a separate technical presentation on:

Plasmid Topology Analysis with the Agilent Fragment Analyzer System.

---

Virus-Like Particles & Vaccine Development

CE Pharm 2025 also covered analytical challenges associated with vaccines and complex particles.

The New Modalities session included:

Separation of Virus Like Particles and Nano-Emulsions for Vaccine Development by Capillary Zone Electrophoresis.

This demonstrates the use of CE beyond conventional soluble protein therapeutics.

---

Conjugate Vaccines

The same scientific session included:

A Novel Derivatization-Based CGE Assay for Quantifying Free Proteins in Conjugate Vaccines

from Merck.

Analytical control of conjugate vaccines can require evaluation of both conjugated material and residual/free components.

---

New Therapeutic Modalities

The official Session IV – New Modalities included applications involving:

• Antibody-drug conjugates
• Virus-like particles
• Nano-emulsions
• Conjugate vaccines

One presentation addressed Chemotype Agnostic DAR with CE-SDS, expanding CE applications into drug-to-antibody ratio analysis for conjugated therapeutics.

---

Regulatory Science

CE Pharm 2025 included a dedicated regulatory session covering analytical procedure development and regulatory expectations.

Official presentations included:

• Reference Data for Peak Integration in Capillary Electrophoresis
• Leveraging Prior Knowledge in Analytical Method Development and Validation: Regulatory Considerations for Protein Products
• Evaluating the Impact of Analytical Method Parameters on Therapeutic mRNA Integrity by Capillary Gel Electrophoresis

Regulatory speakers included representatives from FDA CDER and Health Canada.

---

ICH Q2(R2) and CE

Analytical procedure validation was specifically addressed through the roundtable:

ICH Q2(R2) and CE

alongside discussions of method development, critical reagents, peak integration, and communication with quality and regulatory functions.

Relevant validation concepts can include:

• Specificity
• Accuracy
• Precision
• Range
• Robustness
• Method performance
• Lifecycle management

---

Leveraging Prior Knowledge

The regulatory program included an FDA presentation on:

Leveraging Prior Knowledge in Analytical Method Development and Validation: Regulatory Considerations for Protein Products

highlighting how existing analytical knowledge can potentially inform development of new methods and control strategies.

---

Peak Integration

Peak integration is a practical issue in CE data analysis and was a recurring roundtable topic.

The official program included:

Strategies and Challenges with Peak Integration in CE

in both roundtable sessions.

Challenges may involve:

• Baseline noise
• Peak shoulders
• Peak splitting
• Low-abundance components
• Integration consistency
• Analyst interpretation
• Automated processing
• Data-review practices

---

Communication With QA, Management & Regulatory Teams

Another dedicated discussion addressed:

Communicating Issues with Capillary Electrophoresis Methods to Management, QA, and Regulatory

CASSS notes that common challenges can include migration-time variability, peak-integration difficulties, method validation, instrument performance, and regulatory compliance.

Effective communication requires translating highly technical analytical problems into information relevant to:

Analytical Scientists → Quality Assurance → Management → Regulatory Affairs

---

Critical Reagent Management

CE methods can depend on reagents whose performance directly affects reproducibility.

Official roundtable topics included:

• Strategies and Qualification of Critical Reagents
• Managing Critical Reagents for Capillary Electrophoresis Methods

Important considerations may include:

• Reagent qualification
• Lot-to-lot variability
• Storage
• Stability
• Supplier changes
• Bridging studies
• Documentation

---

Method Troubleshooting

The final day included a dedicated Troubleshooting Workshop, chaired by Timothy Blanc and Cari Sänger van de Griend.

Troubleshooting may require review of:

Instrument → Capillary → Buffer → Sample → Voltage → Temperature → Detection → Integration

This practical focus aligns with CASSS’s stated goal of strengthening real-world use of CE in biotechnology and pharmaceutical laboratories.

---

Technology Advancements in CE

The program also included roundtables specifically dedicated to:

Technology Advancements in CE

allowing discussion of evolving instrumentation, detection systems, analytical formats, and workflow improvements.

---

icIEF

Imaged capillary isoelectric focusing (icIEF) received significant attention in the program.

Topics included:

• Charge heterogeneity
• ADC stability
• Peak characterization
• Protein charge identification
• Fractionation
• Integration with mass spectrometry
• Fluorescence detection

The program included an entire session titled:

From Peak to Shining Peak: Traversing the cIEF Landscape.

---

Next Generation Investigators

CE Pharm 2025 included a dedicated Next Generation Investigators session.

Presentations included:

• Capillary Electrophoresis to Quantify Drug Inhibition of H1N1 and H5N1 Neuraminidases
• Design of a Capillary Isoelectric Focusing Electrospray Ionization-Mass Spectrometry Interface for High Resolution Proteoform Analysis
• Utilizing Fluorescence Detection to Improve icIEF Analysis

The 2025 Next-Generation Investigator Award recipients were Caitlin Kerr, Gianna Pescatore, and Laura Taylor.

---

CE Pharm Award 2025

The 2025 CE Pharm Award was presented to J. Michael Ramsey, Professor at the University of North Carolina at Chapel Hill, in recognition of sustained contributions to practical capillary electrophoresis applications.

His work includes developments in microfluidics, microchip CE, bioinstrumentation, and CE-MS technologies.

---

Keynote Lectures

Microtechnologies for Acquiring Biological Information

J. Michael Ramsey – University of North Carolina, Chapel Hill

The opening keynote explored the evolution of microfabricated analytical systems, microfluidic CE, integrated electrospray ionization, and miniaturized mass-spectrometry technologies.

CE’ing Into the Future: The Role of Capillary Electrophoresis in Innovation for Biological Products

Joel Welch – FDA, CDER

The closing keynote examined the continuing role of CE in innovation and analytical characterization of biological products.

---

Target Audience

This program is targeted to analytical scientists, quality-control professionals, and regulatory-affairs specialists involved in biopharmaceutical development, validation, characterization, and capillary electrophoresis applications.

It is particularly relevant for:

• Clinical Pharmacologists
• Immunologists
• Molecular Pathologists
• Medical Geneticists
• Analytical Scientists
• Biopharmaceutical Scientists
• Protein Characterization Scientists
• Molecular Biologists
• Pharmaceutical Development Scientists
• Quality Control Professionals
• Quality Assurance Professionals
• Regulatory Affairs Specialists
• CMC Scientists
• Method Development Scientists
• Validation Scientists
• Scientists working with vaccines, mRNA, antibodies, ADCs, and other biotherapeutics

CASSS describes CE Pharm as an international forum connecting industry, academia, and regulatory agencies around developments in CE analysis of protein, nucleotide, and small-molecule pharmaceuticals.

---

Who Should Take This Course?

CASSS Sharing Science Solutions CE Pharm 2025 is especially relevant for professionals seeking advanced updates in:

• Capillary electrophoresis
• CE-MS
• CZE
• CE-SDS
• CGE
• CIEF / icIEF
• Biopharmaceutical analytics
• Monoclonal antibodies
• Antibody-drug conjugates
• mRNA analytics
• RNA integrity
• Vaccine analytics
• Plasmid DNA
• Regulatory science
• Analytical procedure validation
• Product characterization
• Quality control

---

Why This Course Is Useful

The strength of CE Pharm 2025 is its focus on translating analytical separation science into practical biopharmaceutical applications.

The program connects:

CE Fundamentals → Method Development → New Modalities → Product Characterization → CE-MS → QC → Regulatory Science → Troubleshooting

This approach allows participants to examine both scientific innovation and the real-world challenges involved in deploying CE methods in regulated pharmaceutical environments.

---

CE Pharm 2025 By the Numbers

CASSS reported 214 attendees, including 73 virtual participants, for the 2025 CE Pharm Symposium.

The meeting included:

• Scientific lectures
• Two keynote presentations
• Panel discussions
• Roundtable sessions
• Poster sessions
• Technical seminars
• A troubleshooting workshop
• Next-generation investigator presentations

---

Major Topics Covered

• Capillary Electrophoresis
• Capillary Zone Electrophoresis – CZE
• Capillary Gel Electrophoresis – CGE
• CE-SDS
• Capillary Isoelectric Focusing – CIEF
• Imaged Capillary Isoelectric Focusing – icIEF
• Capillary Electrophoresis-Mass Spectrometry – CE-MS
• Native Fluorescence Detection
• Protein Therapeutics
• Monoclonal Antibodies
• Antibody-Drug Conjugates – ADCs
• Charge Heterogeneity
• Proteoform Characterization
• mRNA Characterization
• RNA Integrity
• mRNA Vaccines
• Plasmid DNA
• Plasmid Topology
• Cell and Gene Therapy Analytics
• Virus-Like Particles
• Conjugate Vaccines
• Vaccine Purity
• Product Characterization
• Lot-Release Testing
• Stability Testing
• Analytical Method Development
• Analytical Method Validation
• ICH Q2(R2)
• Peak Integration
• Critical Reagents
• CE Troubleshooting
• Regulatory Science
• Quality Control
• CMC Analytics

---

Short Description

CASSS Sharing Science Solutions CE Pharm 2025 is a specialized biopharmaceutical analytical-science symposium held September 7–10, 2025, in Bethesda, Maryland, USA, focused on practical and emerging applications of capillary electrophoresis.

The program covers CE-MS, CZE, CGE/CE-SDS, CIEF/icIEF, native fluorescence detection, ADC and monoclonal-antibody charge heterogeneity, mRNA and RNA integrity, plasmid DNA, virus-like particles, conjugate vaccines, analytical validation, ICH Q2(R2), peak integration, critical reagents, QC, and CE troubleshooting.

Organizer: CASSS – Sharing Science Solutions
Dates: September 7–10, 2025
Location: Bethesda, Maryland, United States
Format: In-Person with Livestreamed Sessions
Primary Focus: Capillary Electrophoresis / Biopharmaceutical Analytical Science
Field: Pharmaceutical & Biotechnology Analysis

---

Topics

• Capillary Electrophoresis Fundamentals and Protein Therapeutic Applications
• Microtechnologies for Acquiring Biological Information
• Capillary Gel Electrophoresis for Gardasil and Gardasil®9 Purity Determination
• Advancement of Capillary Gel Electrophoresis Through the Use of Native Fluorescence Detection
• Charge Heterogeneity Analysis of Antibody Drug Conjugates: Capillary Zone Electrophoresis
• A Tale of Tails: Using the Power of Capillary Electrophoresis for the Analytical Characterization of mRNA
• Development and Optimization of a CGE-LIF Method for RNA Integrity Characterization
• High-Throughput Plasmid DNA Isoform Analysis Using Capillary Gel Electrophoresis
• Reference Data for Peak Integration in Capillary Electrophoresis
• Leveraging Prior Knowledge in Analytical Method Development and Validation
• Evaluating the Impact of Analytical Method Parameters on Therapeutic mRNA Integrity by Capillary Gel Electrophoresis
• Chemotype Agnostic DAR with CE-SDS
• Separation of Virus Like Particles and Nano-Emulsions for Vaccine Development by Capillary Zone Electrophoresis
• A Novel Derivatization-Based CGE Assay for Quantifying Free Proteins in Conjugate Vaccines
• Efficient Charge Variant Analysis of Therapeutic Antibodies Using Direct icIEF Fractionation Combined With NanoLC-MS/MS Peptide Mapping
• Improving ADC Sample Stability in icIEF by Altering Separation Matrix pH
• Protein Charge Identification Using the MauriceFlex
• Capillary Electrophoresis to Quantify Drug Inhibition of H1N1 and H5N1 Neuraminidases
• Design of a Capillary Isoelectric Focusing Electrospray Ionization-Mass Spectrometry Interface for High Resolution Proteoform Analysis
• Utilizing Fluorescence Detection to Improve icIEF Analysis
• High-Performance Native Separation of mAb Proteoforms by CZE-MS
• Advanced Charge Heterogeneity Profiling of Antibody Drug Conjugates via icIEF Fractionation and Mass Spectrometry
• CE-MS: Current Trends and Applications in Biopharmaceutical Development
• ICH Q2(R2) and CE
• Strategies and Challenges with Peak Integration in CE
• Managing Critical Reagents for Capillary Electrophoresis Methods
• mRNA Vaccine CE Applications
• SDS-CGE and CGE Method Development and Application
• Technology Advancements in CE
• CE Method Troubleshooting

• A Novel Derivatization-Based CGE Assay for Quantifying Free Proteins in Conjugate Vaccines

• Advanced Charge Heterogeneity Profiling of a Model ADC via icIEF Fractionation and Mass Spectrometry

• Advanced Electrophoresis Solutions Ltd – Partner Showcase

• Advancement of Capillary Gel Electrophoresis Through the Use of Native Fluorescence Detection

• Advances in Capillary Electrophoresis for Biotherapeutic Development Presented by Bio-techne

• Agilent Technologies Inc – Partner Showcase

• Becoming the CE Expert in Your Organization – Best Practices Exchange

• BioPhase 8800 System Advancing Capillary Electrophoresis With Native Fluorescence Detection

• Bio-Techne and Protein Simple – Partner Showcase

• Capillary Electrophoresis to Quantify Drug Inhibition of H1N1 and H5N1 Neuraminidases

• CASSS Welcome and Introductions

• CE Pharm 2025 Scientific Program and Summary Infographic

• CE-MS – Current Trends and Applications in Biopharmaceutical Development

• Charge Heterogeneity Analysis of Antibody Drug Conjugates Capillary Zone Electrophoresis

• Charge Isoform Identification using the MauriceFlex

• Closing Remarks and Invitation to CE Pharm 2026

• Communicating Issues with Capillary Electrophoresis Methods to Management, QA, and Regulatory

• Design of a Capillary Isoelectric Focusing Electrospray Ionization-Mass Spectrometry Interface for High Resolution Proteoform Analysis

• Development and Optimization of a CGE-LIF Method for RNA Integrity Characterization using SCIEX 9000 RNA Kit

• Empowering a Speak Up Culture in the Biopharmaceutical Industry – Promoting Psychological Safety

• Evaluating the Impact of Analytical Method Parameters on Therapeutic mRNA Integrity by Capillary Gel Electrophoresis

• Forgotten CE Technologies – CGE, ITP, Affinity CE, Taylor Dispersion

• High-Performance Native Separation of mAb Proteoforms by CZE-MS Under Native and Denaturing nanoESI Conditions

• How Fast Can We Go Without Sacrificing Quality

• ICH Q2 R2 and CE

• Improving ADC Sample Stability in icIEF by Altering Separation Matrix pH a Case Study

• Keynote I Microtechnologies for Acquiring Biological Information CE Pharm Award

• Label-Free Native Fluorescence for High-Sensitivity Protein Analysis Using a Multi-Capillary Electrophoresis System

• Leveraging Prior Knowledge in Analytical Method Development and Validation Regulatory Considerations for Protein Products

• Lunch and Learn Technical Seminar Presented by SCIEX

• Managing Critical Reagents for Capillary Electrophoresis Methods

• mRNA Vaccine CE Applications

• Partner Showcases: Advanced Electrophoresis Solutions Ltd., Bio-Techne, and SCIEX

• Plasmid Topology Analysis with the Agilent Fragment Analyzer System

• Reference Data for Peak Integration in Capillary Electrophoresis Another Successful CASSS Project

• SDS-CGE and CGE Method Development and Application

• Separation of Virus Like Particles and Nano-Emulsions for Vaccine Development by Capillary Zone Electrophoresis

• Session I – V Panel Discussions

• Session VI – Next Generation Investigators

• Session VII – CE-MS and Peak ID Product Characterization and Panel Discussion

• Strategies and Challenges with Peak Integration in CE

• Strategies and Qualification of Critical Reagents

• Technology Advancements in CE

• Troubleshooting Workshop

• Unraveling Biopharmaceutical Heterogeneity with Advanced Imaged Capillary Isoelectric Focusing Methodologies

• Utilizing Fluorescence Detection to Improve icIEF Analysis